A longer-range question

EKF Diagnostics, the Penarth-based diagnostics group in the FTSE AIM UK 50, has issued no regulatory news since 29 September 2026, when it announced the conclusion of its share buyback. (LSE:EKF) With second-half delivery covered previously, this piece steps back to a longer horizon: the five-year plan, reiterated in interim results on 15 September, to build a Business generating more than £80m of Revenue and £20m of adjusted EBITDA by 2029.

On the LSE delayed price for the 3 November session, captured shortly after midnight on 4 November, the shares were 23.4p, down 0.43%. (LSE:EKF) Using the 427,968,392 shares the company said would be in issue after its final buyback cancellation, that implies a Market Value of roughly £100m, our calculation.

The arithmetic from here

EKF cites consensus forecasts for 2026 of £54.6m revenue and £13.6m adjusted EBITDA. (LSE:EKF) By our calculation, reaching £80m by 2029 from that base would require compound revenue growth of about 13.6% a year over three years, and lifting EBITDA to £20m would need a similar rate, around 13.7%. The implied 2029 EBITDA margin, 25%, is close to the roughly 24.9% embedded in 2026 consensus, so the plan relies mainly on growth rather than Margin expansion.

For context, first-half 2026 revenue was £25.0m, broadly flat on a like-for-like basis, with adjusted EBITDA of £5.9m, a margin of about 23.6% on our numbers. (LSE:EKF) The company attributes the flat half to delayed orders and tenders that it expects largely to recover in the second half.

The three pillars

The plan rests on three pillars. The first is contract Manufacturing and fermentation, now rebranded as Nexus Bioworks and centred on the enzyme Facility in South Bend, Indiana, which opened in October 2023. Fermentation revenue rose 14% to £1.6m in the half and contract manufacturing 25% to £1.0m, although management does not expect the latter's growth rate to continue into the second half.

The second pillar is beta-hydroxybutyrate, or β-HB, testing reagents, where revenue grew 4% to £7.4m after some distribution partners adjusted inventory. The third is point-of-care haematology, where revenue was £7.8m; the company points to Hemo Control consumables capacity expansion, US blood bank contracts and shipments to Egypt and Peru. Outside the pillars, diabetes testing contributed a flat £5.5m, and the April purchase of Beep Insights technology is intended to strengthen the smaller sports performance lactate range with AI-enabled features.

Funding the plan

Cash stood at £16.0m at 30 June 2026, of which £2.4m sat in a Russian Subsidiary subject to regulatory restrictions. The buyback, launched in May 2025 and concluded in September, repurchased 21,125,398 shares at an average of 25.93p, or about £5.5m by our estimate. Its completion leaves more cash for investment, although the company has not announced a new Capital allocation framework.

What could get in the way

Growth of roughly 13-14% a year would be well above the flat revenue reported in the first half, and administrative expenses rose to £10.0m from £9.2m as EKF invested in sales and marketing, so the target leaves little room for further timing slippage. Point-of-care revenue depends on large tenders and government screening programmes whose timing EKF does not control. Hemo Control capacity expansion has also seen commissioning delays, with first changes now expected in 2027. Sanctions continue to affect Russian sales, and lower reimbursement in HbA1c testing is pushing Demand towards cheaper products.

Checkpoints ahead

The first test is whether full-year 2026 results match the £54.6m and £13.6m consensus the company referenced; EKF has not yet dated its year-end trading update or results. After that, annual growth in Nexus Bioworks, β-HB and haematology will show whether the business is tracking the trajectory the 2029 plan implies. The company has not published interim milestones for 2027 or 2028.